As the med tech industry zeroes in on noninvasive tests that rapidly diagnose concussions, Quanterix and Banyan Biomarkers are joining forces to develop products that could provide a new standard of care for patients.
Bayer is pushing forward with a new heart-failure treatment that could eventually contend with Novartis' blockbuster-in-waiting Entresto, mapping out a wide Phase III program for its oral drug.
The legalization of marijuana for medical and recreational use in a growing number of states like Colorado has brought plenty of controversy. But that's not stopping one Denver company from bringing its line of cannabis-based health products to the veterinary world.
UCL has made Elsevier's PharmaPendium available to its researchers. The United Kingdom academic institution has subscribed to the resource to support its staffers' research into drug repurposing and the personalization of treatments.
While there were plenty of health startups among the more than 30 companies featured at the first ever White House Demo Day in August, only one could boast it's already making a splash in animal health: New York based Suneris. During the event, the company's founder, Joe Landolina, demonstrated Vetigel, an algae-derived product designed to stop traumatic bleeding in 10 seconds.
The Diabetes Research Institute (DRI) has had positive results in the first patient in a Phase I/II, pilot trial of a technique it expects could result in a bioengineered mini organ. This could mean a breakthrough in the race to develop an artificial pancreas that produces insulin in Type 1 diabetic patients.
In an effort to widen the reach of its flu vaccines business--and to develop new vaccines on a familiar platform--Takeda has inked an agreement to expand its rights to the Vero cell technology platform for vaccines production from Florida's Nanotherapeutics, Inc.
Pfizer's meningitis B vaccine Trumenba won the FDA's blessing nearly a year ago based on impressive midstage results and a national unease about the infection spreading on college campuses. Now, just in time for the back to school season, the New York-based pharma on Friday announced positive late-stage results in nearly 7,000 individuals that confirmed the vaccine's effectiveness against certain meningits B strains.
MorphoSys has moved to add targets for its immuno-oncology arsenal. The agreement sees MorphoSys gain access to tumor-associated peptides discovered by its compatriot Immatics Biotechnologies in exchange for some of its antibodies, with both companies paying out milestones as their respective programs advance.
Thanks to pharma's R&D cost-cutting efforts, the CRO industry will expand at nearly a 10% clip through 2019, a new report says, citing trends that many industry-watchers will find familiar.